BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+44.04%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$1.32B
AUM Growth
+$1.32B
(+39%)
Cap. Flow
+$122M
Cap. Flow
% of AUM
9.27%
Top 10 Holdings %
Top 10 Hldgs %
60.28%
Holding
65
New
6
Increased
15
Reduced
13
Closed
8
Top Buys
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$94M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$75.2M |
| 3 |
Cytokinetics
CYTK
|
$32.3M |
| 4 |
Phathom Pharmaceuticals
PHAT
|
$24.5M |
| 5 |
Xoma
XOMA
|
$23.1M |
Top Sells
| 1 |
Galapagos
GLPG
|
$46.6M |
| 2 |
FWP
Forward Pharma A/S American Depositary Shares
FWP
|
$36M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$24.1M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$24.1M |
| 5 |
Merus
MRUS
|
$20.7M |
Sector Composition
| 1 | Healthcare | 95.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $132M | 9.98% | 2,179,735 +1,244,187 | +133% | +$75.2M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $119M | 8.99% | 3,079,155 +235,010 | +8% | +$9.05M |
|
3
AC Immune
ACIU
$205M
| $96.6M | 7.33% | 11,342,505 +44,594 | +0.4% | +$380K |
|
|
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $94M | 7.13% | +1,716,734 | New | +$94M |
|
|
5
Cytokinetics
CYTK
$4.23B
| $76.5M | 5.8% | 7,206,458 +3,040,900 | +73% | +$32.3M |
|
|
6
Xoma
XOMA
$392M
| $72.1M | 5.47% | 2,642,405 +845,463 | +47% | +$23.1M |
|
|
ARQL
7
DELISTED
Arqule Inc
ARQL
| $59.5M | 4.51% | 2,978,683 +870,021 | +41% | +$17.4M |
|
|
CALA
8
DELISTED
Calithera Biosciences, Inc
CALA
| $54.6M | 4.14% | 9,559,642 +2,809,160 | +42% | +$16M |
|
|
MTEM
9
DELISTED
Molecular Templates, Inc.
MTEM
| $47M | 3.56% | 3,358,332 -22,272 | -0.7% | -$311K |
|
|
10
Merus
MRUS
$4.98B
| $44.6M | 3.38% | 3,169,654 -1,469,759 | -32% | -$20.7M |
|
|
CBIO
11
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $38.9M | 2.95% | 7,361,801 | – | – |
|
12
Arcus Biosciences
RCUS
$1.13B
| $36.1M | 2.74% | 3,579,023 | – | – |
|
|
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $35.7M | 2.71% | 7,783,001 +4,017,833 | +107% | +$18.4M |
|
14
Replimune Group
REPL
$422M
| $33.1M | 2.51% | 2,309,109 +559,400 | +32% | +$8.03M |
|
15
Kura Oncology
KURA
$686M
| $27.5M | 2.08% | 1,998,276 | – | – |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $25.6M | 1.94% | 1,949,075 +207,475 | +12% | +$2.72M |
|
|
17
Phathom Pharmaceuticals
PHAT
$864M
| $24.5M | 1.86% | +785,851 | New | +$24.5M |
|
|
PVLA
18
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $19.4M | 1.47% | 5,349,905 | – | – |
|
|
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $16.7M | 1.27% | 17,426,968 | – | – |
|
20
Immunovant
IMVT
$2.56B
| $15.9M | 1.2% | +999,996 | New | +$15.9M |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $15.5M | 1.17% | 1,764,784 | – | – |
|
22
AnaptysBio
ANAB
$569M
| $15.3M | 1.16% | 939,565 +585,747 | +166% | +$9.52M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $14.7M | 1.12% | 183,834 -253,731 | -58% | -$20.3M |
|
24
ESSA Pharma
EPIX
$11.4M
| $14.5M | 1.1% | 2,640,565 | – | – |
|
25
MEI Pharma
MEIP
$160M
| $13.3M | 1.01% | 5,346,272 +3,125,000 | +141% | +$7.75M |
|